Metro Inc
TSX:MRU

Watchlist Manager
Metro Inc Logo
Metro Inc
TSX:MRU
Watchlist
Price: 99.85 CAD -0.03% Market Closed
Market Cap: 21.4B CAD

Q3-2025 Earnings Call

AI Summary
Earnings Call on Aug 13, 2025

Sales Growth: Metro reported third quarter sales of $6.9 billion, up 3.3% from last year, with strong growth in both food and pharmacy segments.

Margin Expansion: Gross margin rose to 19.8% from 19.6% last year, helped by productivity gains and reduced shrink in food retail.

EPS & Profitability: Adjusted net earnings reached $332 million, up 8.8%, and adjusted EPS grew 12.6% to $1.52.

Store Network: Eight new stores opened and major expansions/renovations completed at twelve stores, with further openings planned in Q4.

Competitive Environment: Management noted intensified competition with increased promotional activity and new store openings.

Tariff Impact: About 20% of vendor price increase requests are now tariff-related, which management is working to minimize for consumers.

Online Growth: Online sales grew 14%, driven by expanded delivery partnerships and increased click-and-collect usage.

Sales and Same-Store Performance

Metro delivered 3.3% sales growth in the quarter, with food same-store sales up 1.9% and pharmacy same-store sales up 5.5%. Prescription and front-end pharmacy sales also posted strong growth. While food same-store sales growth slowed slightly compared to the previous quarter, management emphasized solid two-year stacked performance and overall satisfaction with results.

Margins and Productivity

Gross margin improved to 19.8%, up 20 basis points year-over-year. This was attributed to gains in productivity from distribution centers and improvements in shrink reduction on the food side. Management highlighted the successful ramp-up and contribution of new automated distribution centers, particularly in Terrebonne and Toronto, to margin gains.

Competitive and Promotional Landscape

The competitive environment intensified during the quarter, with a noticeable uptick in promotional activity and new store openings from competitors. Despite this, Metro reported holding its own in terms of market share and tonnage, particularly in its conventional banners. Promotional penetration and private label sales remain high, reflecting consumer focus on value.

Tariffs and Vendor Price Increases

Management stated that around 20% of vendor price increase requests are now related to tariffs, affecting about 3,000 SKUs. These requests are typically in the high single digits as a percentage, but Metro negotiates to minimize the impact on consumers. While some price increases are being accepted, the overall effect remains manageable and in line with CPI.

Online and E-commerce

Online sales increased by 14% in the quarter, driven by click-and-collect, the launch of home delivery at Super C and Food Basics, and expanded partnerships with third-party delivery providers like DoorDash, Instacart, and Uber. Metro continues to pursue a multi-service model combining its own delivery, click-and-collect, and third-party offerings, with steady growth across all channels.

SG&A and Cost Control

SG&A expenses were $702 million, or 10.2% of sales, similar to last year. The company cycled out duplicate distribution center transition costs, but this was offset by general inflationary pressures, recurring costs from new facilities, and higher e-commerce-related fees. Management expects modest SG&A leverage in coming quarters.

Pharmacy and GLP-1 Trends

Pharmacy performance remained strong, with prescription sales growth driven by specialty medications, GLP-1s, and clinical services. Management addressed questions about GLP-1 patent expiry, noting potential for generics to become available for Ozempic, but not yet for Wegovy. If generics enter, pharmacy margins may benefit, though the distribution business could see some margin dilution offset by higher volumes.

Store Expansion and Investment

Metro opened 8 new stores and completed 12 expansions or renovations, increasing food retail square footage by 0.9%. The opening of additional stores is planned in the fourth quarter, including more discount banners and a new Adonis in Ontario. Capital expenditures declined as distribution center investments were largely completed.

Revenue
$6.9B
Change: Up 3.3% versus Q3 last year.
Food Same-Store Sales
1.9%
No Additional Information
Pharmacy Same-Store Sales
5.5%
No Additional Information
Prescription Sales Growth
6.2%
No Additional Information
Front-End Pharmacy Sales Growth
4%
No Additional Information
Gross Margin
19.8%
Change: Up from 19.6% in Q3 last year.
Operating Expenses
$702M
No Additional Information
Operating Expenses as % of Sales
10.2%
Change: Similar level to Q3 last year.
EBITDA
$656M
Change: Up 5.7% year-over-year.
EBITDA Margin
9.5%
Change: Up 20 bps over Q3 2024.
Depreciation and Amortization Expense
$185M
Change: Up $11M.
Net Financial Costs
$45M
Change: Down from $47M last year.
Effective Tax Rate
24.1%
Change: Down from 25.9% in Q3 last year.
Adjusted Net Earnings
$332M
Change: Up 8.8%.
Adjusted EPS
$1.52
Change: Up 12.6% year-over-year.
Capital Expenditures
$146M
Change: Down $41M versus last year.
Share Repurchases
5.7M shares for $562M
No Additional Information
Average Share Price for Repurchases
$98.55
No Additional Information
Online Sales Growth
14%
No Additional Information
Food Retail Network Square Footage Increase
194,000 square feet or 0.9%
No Additional Information
Revenue
$6.9B
Change: Up 3.3% versus Q3 last year.
Food Same-Store Sales
1.9%
No Additional Information
Pharmacy Same-Store Sales
5.5%
No Additional Information
Prescription Sales Growth
6.2%
No Additional Information
Front-End Pharmacy Sales Growth
4%
No Additional Information
Gross Margin
19.8%
Change: Up from 19.6% in Q3 last year.
Operating Expenses
$702M
No Additional Information
Operating Expenses as % of Sales
10.2%
Change: Similar level to Q3 last year.
EBITDA
$656M
Change: Up 5.7% year-over-year.
EBITDA Margin
9.5%
Change: Up 20 bps over Q3 2024.
Depreciation and Amortization Expense
$185M
Change: Up $11M.
Net Financial Costs
$45M
Change: Down from $47M last year.
Effective Tax Rate
24.1%
Change: Down from 25.9% in Q3 last year.
Adjusted Net Earnings
$332M
Change: Up 8.8%.
Adjusted EPS
$1.52
Change: Up 12.6% year-over-year.
Capital Expenditures
$146M
Change: Down $41M versus last year.
Share Repurchases
5.7M shares for $562M
No Additional Information
Average Share Price for Repurchases
$98.55
No Additional Information
Online Sales Growth
14%
No Additional Information
Food Retail Network Square Footage Increase
194,000 square feet or 0.9%
No Additional Information

Earnings Call Transcript

Transcript
from 0
Operator

Good morning, ladies and gentlemen, and welcome to the Metro Inc. 2025 Third Quarter Results Conference Call. [Operator Instructions]. Also note that this call is being recorded on Wednesday, August 13, 2025.

And I would like to turn the conference over to Sharon Kadoche, Director, Investor Relations and Corporate Finance. Please go ahead.

S
Sharon Kadoche
executive

Good morning, everyone, and thank you for joining us today. Our comments will focus on the financial results of our third quarter, which ended on July 5. With me today is Mr. Eric La Fleche, President and CEO; Nicolas Amyot, Executive VP and CFO; Marc Giroux, Chief Operating Officer; and Jean-Michel Coutu, President of the Pharmacy division.

During the call, we will present our third quarter results and comment on its highlights. We'll then be happy to take your questions.

Before we begin, I would like to remind you that we will use in today's discussion different statements that could be construed as forward-looking information. In general, any statement, which does not constitute a historical fact may be deemed a forward-looking statement. Words or expressions such as expect, intend, are confident that, will and other similar words or expressions are generally indicative of forward-looking statements. The forward-looking statements are based upon certain assumptions regarding the Canadian food and pharmaceutical industries, the general economy, our annual budget and our 2025 action plan.

These forward-looking statements do not provide any guarantees as to the future performance of the company and are subject to potential risks, known and unknown as well as uncertainties that could cause the outcome to differ materially. Risk factors that could cause actual results or events to differ materially from our expectations as expressed in or implied by our forward-looking statements are described under the Risk Management section in our 2024 annual report.

We believe these forward-looking statements to be reasonable and pertinent at this time and represent our expectations. The company does not intend to update any forward-looking statements, except as required by applicable law.

I will now turn the call over to Nicolas.

N
Nicolas Amyot
executive

Okay. Thank you, Sharon, and good morning, everyone. I will now go over our Q3 results. Total sales reached $6.9 billion, an increase of 3.3% versus the third quarter last year. Food same-store sales grew by 1.9% in the quarter, while pharmacy same-store sales grew by 5.5%, supported by a 6.2% growth in prescription sales and a 4% growth in front-end sales.

Our gross margin stood at 19.8% of sales versus 19.6% in the same quarter last year. The year-over-year increase is partly attributable to productivity gains in our food distribution centers as well as shrink improvement in food retail activities.

Operating expenses were $702 million, representing 10.2% of sales, a similar level to our third quarter last year. We benefited from the fact that we cycled transition duplicate costs last year related to our Terrebonne automated distribution center, but these benefits were offset by inflationary pressures, operational expenses related to our Fresh Phase 2 DC in Toronto as well as an increase in fees related to the growth of our online partnership sales.

EBITDA for the quarter totaled $656 million, up 5.7% year-over-year, while EBITDA as a percentage of sales stood at 9.5% this quarter, an increase of 20 basis points over Q3 2024. Total depreciation and amortization expense for the quarter was $185 million, up $11 million. The increase in depreciation and amortization expense is mainly driven by retail investments as well as by the commissioning of investments in our supply chain, including the final phase of our fresh distribution center in Toronto last summer and some automation technology in the Pharmacy division.

Net financial costs for the third quarter were $45 million compared to $47 million last year. The decrease is mainly attributable to a lower interest expense on net debt, partly offset by lower capitalized interest. Our effective tax rate of 24.1% is lower than the effective tax rate of 25.9% in the third quarter last year, largely driven by the Terrebonne tax holiday, consistent with what we have reported in our first 2 quarters this year.

Adjusted net earnings were $332 million compared to $305 million last year, an increase of 8.8%, while adjusted net earnings per share amounted to $1.52 versus $1.35 last year, and that's up 12.6% year-over-year. Our capital expenditures for the third quarter totaled $146 million, down $41 million versus last year. As expected, the lower CapEx level is mainly the result of the completion of our automated distribution centers.

On the food retail side, after 40 weeks, we opened 8 new stores, including 3 conversions and carried out major expansions and renovations at 12 stores for a net increase of 194,000 square feet or 0.9% of our food retail network square footage. Under our normal course issuer bid program, as of August 1, we have repurchased 5.7 million shares for a total consideration of $562 million, representing an average share price of $98.55.

To conclude, we have delivered solid Q3 results, and I will now turn it over to Eric for more color on our performance. Thank you.

E
Eric La Flèche
executive

Thank you, Nicolas, and good morning, everyone. We are pleased with our results in the third quarter as our teams continue to deliver on our customer promises, in particular, good value with competitive everyday prices, effective promotional strategies, our full range of private label products and our loyalty program.

For the quarter, total sales grew by 3.3%, EBITDA by 5.7% and adjusted EPS by 12.6%. Starting with food, same-store sales were up 1.9% and 4.4% over 2 years. Discount continues to drive same-store sales growth faster than Metro with the gap between both remaining stable. Our internal food inflation basket inflation was in line with the reported food CPI of 3.1%.

We continue to see inflationary pressures on certain commodity prices, namely in the meat category. The introduced tariffs and counter tariffs are also a contributing factor to food inflation as we continue to receive price increase requests from our vendor partners.

Teams continue to negotiate to minimize the impact on consumers and for now, the effect remains manageable. During the quarter, transaction count was slightly down, but offset by an increase in the average basket. Promotional penetration remains at elevated levels and private label sales continue to outperform national brands. The competitive environment intensified somewhat in the quarter, and we held our own in terms of market share and tonnage.

The Buy Canada movement is also persisting with sales of Canadian products outpacing total sales, albeit at a slower pace. Online sales grew by 14% for the quarter. Growth is being driven by the ramp-up of click-and-collect services and also the launch of home delivery at Super C and Food Basics as well as third-party marketplaces.

Also, we announced in mid-July, the expansion of third-party delivery services to include DoorDash in Quebec and Ontario. This is in addition to Instacart and Uber with whom we've been operating for a few years now.

Turning to pharmacy. The business sustained its positive momentum and delivered another strong quarter with comp sales of 5.5% for a 2-year stack of 11%. Prescription sales were up 6.2%, driven by continued organic growth, specialty medications, GLP-1s and clinical services. Commercial sales were up 4%. The strong performance was driven by growth in OTC, HABA and cosmetics.

As Nicolas mentioned, we are on track with our plan to accelerate the development of our growing discount banners as we successfully opened 5 new stores in the quarter. In our fourth quarter, we plan on opening another 6 stores, including 2 conversions, bringing the total to 14 in fiscal 2025.

The new Adonis store will open in London tomorrow, our fifth Adonis in Ontario. As we begin our fourth quarter, we continue to see similar market trends and our teams continue to focus on delivering the best value possible to our customers in this uncertain economic environment.

Finally, we are confident that our sustained investments in our retail networks and supply chain, combined with strong execution, will continue to fuel our growth and create long-term shareholder value.

Thank you, and we'll now be happy to take your questions.

Operator

[Operator Instructions]. And your first question will be from Mark Carden at UBS.

M
Mark Carden
analyst

So strong performance, but a notable step down from last quarter. I was wondering if you could detail your comp performance within the quarter, how that trended? And then any early read on how 4Q is looking?

E
Eric La Flèche
executive

Well, I think we had a strong quarter, and I don't agree that we've had a notable step down, certainly not in our sales top line and bottom line and EPS growth, and we're pleased with our performance.

If you're referring to the slightly lower same-store sales growth on the food side, I think you have to look at it over 2 years. I think comp sales are a function of what you're comping. We've had steady and strong comps for many, many quarters. We had good comps this quarter. Yes, it was a bit softer than the previous quarter. But if you look at it on a 3-year basis, we're pleased with our performance.

M
Mark Carden
analyst

Great. And just as a follow-up, I'm curious what your view is on the consumer. Has anything changed in their shopping habits over the last quarter? Any more trade down happening within categories?

E
Eric La Flèche
executive

I wouldn't say there's more trading down. The search for value has been ongoing for over a couple of years now or more. So it's the same trend. I referred to it in my opening comments. People are searching for value. Promotional levels are high, private label sales are high. So we're seeing pretty much the same picture on the consumer side.

Some meat prices have -- there's a strong inflation in the meat category. So we're seeing some adjustments. So call it maybe some trading down or higher promotional penetration in the meat category because our costs have gone up substantially on the meat side and some retail prices are reflecting that. So that's what I would say.

Operator

Next question will be from Tamy Chen at BMO Capital Markets.

T
Tamy Chen
analyst

Eric, could you elaborate a bit more on your comment that you saw the competitive environment intensify somewhat in the quarter? Is this both your region provinces in the country? Is it coming from a certain few competitors or pretty broad? And I assume you're talking about like not just promo penetration, but specifically like promotional intensity? And is this a fairly meaningful step-up in that?

E
Eric La Flèche
executive

I don't want to spook anybody. We are operating in a competitive environment. It's always competitive. We noticed a bit of an uptick in promotional activity, openings of new stores, conversion. So there's been quite a bit of activity in the market out there in Q3. So that intensifies competition. So I think it's normal or it's expected, I should say.

We operate in a competitive environment. I think prices are rational, but it did intensify a bit in Q3. That's what I'd like to say. Is that clear, Tamy? I don't know if that answers your question. We're not identifying anybody. It's just that at large, we noticed an uptick in the competitive intensity, promotional pricing due to market conditions. So it was -- it intensified somewhat a little bit in Q3.

T
Tamy Chen
analyst

Yes, I see what you mean. And are you able to talk a bit about your conventional banners. So I noticed you said discount is still driving the comp. But how is your conventional banners doing in your 2 regions? I think in Quebec, you picked up some share, but I'm curious how it's doing in Ontario because I think there are some competitors that have been fairly aggressive rolling out new discount square footage, particularly in Ontario.

E
Eric La Flèche
executive

So we're pleased with our conventional stores. Our Metro stores in both provinces are holding their own really well versus their conventional peers as measured by Nielsen GDM conventional. We're pleased with our performance in both markets. So we're holding our own.

Clearly, there's been more growth in discount than in conventional over the past few years, that is continuing, albeit at a slower pace, but it's still continuing. So overall, I'm not saying our conventional stores are gaining market share. But relative to the competitive set of conventional stores, we're holding our own and pleased with our performance.

Operator

Next question will be from Irene Nattel at RBC Capital Markets.

I
Irene Nattel
analyst

Just switching gears a little bit. You noted, Eric, in your commentary that you're starting to -- that you're getting more price increase requests from vendors that are tariff related. Can you just talk a little bit about that, what the magnitude of the price increases are, efforts to offset and the like?

E
Eric La Flèche
executive

Yes. So the number of price requests is similar. It's -- we're still in the normal environment, but those related to tariffs, they represent about 20% of the increases demand that we're receiving from vendors. There's about 3,000 SKUs right now that are affected by tariffs that we've received increases and accepted increases related to tariffs.

So we negotiate hard, and it has to be with the code number, and it has to be proven and all of that. So we're talking about high single digits percentage or the asks. We don't necessarily finish there, but we negotiate as best we can to minimize the impact on our consumers in this environment where everybody is searching for value and everybody is more price sensitive.

So we're working hard with our vendors to minimize that impact. The counter tariff started in March. Some suppliers waited to impose cost increases on us, but some of those have now started to flow in on the HABA side, one large U.S. CPG company, we started to see some price increases that we've had to take in this month in August. So we're seeing some of that. But like I said in my opening statement, it's manageable. We're still in line with CPI. CPI is around 3%. We'd like it to be 2%, but we're at 3% these days.

I
Irene Nattel
analyst

And in those categories where you are seeing the price increases, are you seeing an acceleration in, let's say, trade down to private label to the extent that it exists in those categories and increased penetration? Or are you seeing consumers just kind of say, yes, we're just going to switch out of these products, if possible?

E
Eric La Flèche
executive

I don't have a specific example for you, but I think those increases contribute to the rise or the growth in sales for private label. It's a contributing factor, not the only one, but -- it certainly helps. The tariffs -- the price increases related to tariffs that I just referred to of just on the HABA side are very recent. So I can't really point to a change in consumer behavior there.

On the food side, what we've seen since March, those products that have been affected, like we said before, we search for other suppliers in other countries just to minimize prices and maintain quality. So the consumer, we've been able to navigate and to provide value to our customers despite these tariffs. That's why I say it's been manageable. So hopefully, it will stay that way.

Operator

Next question will be from Michael Van Aelst at TD Cowen.

M
Michael Van Aelst
analyst

Just to start off, can I clarify on the same-store sales growth, when you're talking about 2-year stack, are you looking at it that way because of your -- you benefited in May of last year when there was a boycott on a competitor and therefore, had a bigger boost last year and you're cycling that now? And if so, did you see your same-store sales growth reaccelerate in June after you cycle the May boycott?

E
Eric La Flèche
executive

Well, this "boycott" may have helped us a little bit last year, so we had to comp that. That's one of the reasons I referred to the 2-year number to give you a better picture. We're not going to give you details on our sales. We don't give guidance on our sales in June, July or August or whatever. The quarter ended early July. So it's all pretty much behind us now.

M
Michael Van Aelst
analyst

All right. And then on the distribution centers that have opened, can you provide some color as to how they performed during Q3 in terms of pick efficiencies and service the stores and how that is different heading into Q4?

E
Eric La Flèche
executive

Well, our food DCs in Terrabonne and Toronto Fresh Phase 2, we're very pleased with our performance. If I look at cost per case productivity numbers, we're very pleased with the performance. It did contribute to our gross margin improvement of 20 basis points, those productivity gains -- so we're pleased with the performance.

We're on track, pretty much on track with our -- or ahead of our plan related to our DC performance. So that performance of Q3 is continuing into Q4. So I'm not really concerned by that. It's hard work, but ramping up well. I don't know if that answers your question.

M
Michael Van Aelst
analyst

Because your outlook statement changed a bit. So you talked about productivity initiatives or efficiencies and then you talked about service to the stores. And it seems like you took out the part of this quarter where you're saying you're looking to improve service to the stores. So I was wondering...

E
Eric La Flèche
executive

We took it out because the transition is over and our service to our stores is very good. So we're not concerned by that. It's done. So we're focused on productivity, efficiency gains. The service to the stores is satisfactory, and we're pleased with that performance. So we're always focused on service to our stores, but it's not a specific focus going forward.

M
Michael Van Aelst
analyst

Okay. And I know there's no kind of finish line, but when do you -- how much longer do you expect it to be before you get a run rate of efficiencies in the DCs that is in line with business plan or at least in line with what you now expect?

E
Eric La Flèche
executive

Well, I think we're there now. We're in line with our business plans. The freezer -- both freezers in Quebec and Ontario were ahead of plan and very pleased with the performance of productivity.

The automated fresh in Toronto is a bit more of a challenge. The supply chain has to adjust. The packaging from our vendors has to adjust to be automatable. So we'd like a higher percentage of cases to go through the automation system.

We're close to where we want to be, but we're not there yet. So there's room to improve on the fresh side. It may take a little more time as, as I said, the supply chain adjusts. The rest, fresh meat, frozen meat in both provinces, deli, dairy, we're very pleased with our performance.

Operator

Next question will be from Yiyang Liu at Scotiabank.

Y
Yiyang Liu
analyst

I wanted to ask about GLP-1s, in particular, Ozempic and Wegovy. Can you talk about the state of [ produced ] product business and how you expect the expiry of those weight loss drugs patent is expected to impact your generics business? And how these transitions have played out historically?

E
Eric La Flèche
executive

I'll let Jean-Michel take this one.

J
Jean-Michel Coutu
executive

Yes. So can you hear me?

E
Eric La Flèche
executive

Can you hear him well? Yes?

J
Jean-Michel Coutu
executive

Yes. So it's -- right now, it's the -- maybe to clarify one thing. The only patent that's being challenged is for Ozempic. Wegovy, which is the one that actually has the indication for weight loss is not going to be challenged in terms of its patent since it's fairly new in Canada. It's too early to tell how it's going to happen with Health Canada in terms of approval.

We know that there are some companies that have submitted to have those patents broken. Obviously, if that's the case, we're going to work with our vendor community and our partners to try to get a product equivalent as we always do with every generic molecule that has sufficient volume.

Usually, the way it works is when a molecule becomes generic, the networks convert as quickly as -- the pharmacies convert as quickly as they can because it is margin accretive for them within their stores. And when we talk about margin here, it's really professional allowances, which they have to reinvest in their stores according to the law in Quebec. So it is margin, but it's margin that needs to be guided towards certain expenses within their stores. So I hope that answers a little bit your question.

E
Eric La Flèche
executive

And just to complement on that. For the company here as a distributor, if those drugs become generic, we will make a generic fee -- a distribution fee on the generic lower price. So there could be a dilutive impact here for that. But volume usually picks up the slack.

Y
Yiyang Liu
analyst

Yes. And then I guess just another follow-up. I wanted to double-click on the performance between your 2 provinces. I'm wondering in particular about the exposure to certain Ontario markets that are perhaps more impacted by the tariff environment. Have you noticed any consumer behavior changes there?

E
Eric La Flèche
executive

Not that we can point out more specifically what we're describing as the consumer environment, competitive environment is -- concerns both of our markets.

Operator

Next question will be from Mark Petrie at CIBC.

M
Mark Petrie
analyst

I wanted to just ask about the SG&A rate. Maybe if you can give some more specifics about sort of the puts and takes there.

And then, Eric, you've commented about Fresh Phase 2, but hoping you could give some sense of when you would expect that facility to turn to a tailwind when it comes to SG&A.

N
Nicolas Amyot
executive

Mark, maybe I'll start with SG&A. As you -- as I've mentioned, SG&A was at 10.2% of sales this quarter, similar to last quarter. I mentioned we cycled out transition costs. So obviously, that was a tailwind for us. However, there's overall inflation in pretty much all the categories of expenses that flow into SG&A. And we're happy with the cost control performance we've had, but we have seen SG&A inflation pressures there for sure.

Also, the commissioning of our distribution center, Fresh Phase 2 in Toronto last summer is now driving recurring expenses that are now in SG&A and that we are going to be incorporated going forward.

And finally, I would say, as I mentioned, that the ongoing growth of the e-commerce business is driving fees to our partners in SG&A. And I guess, nothing abnormal, but consistent with the growth in e-commerce sales. So overall, I would say, happy with the performance on SG&A.

E
Eric La Flèche
executive

And more specific to the Fresh Phase 2, we're -- like I said, we're on plan. We're on track with the ramp-up that we expected. I said automation, if we could automate -- if we can put through more products through the automation machine, it would be even better. Again, that takes time because it's a supply chain, it's a vendor adjustment. So it's generally a tailwind. We're pleased with the performance. We're reaching our objectives, and there's going to be room for more as the industry adjusts. So I don't know how I give you a clearer answer.

M
Mark Petrie
analyst

Okay. Fair enough. With specific to the online growth, is it fair to say that a lot of that is -- the growth is being driven by sort of short time frame delivery, third-party orders? And I guess, what's your latest thinking about your infrastructure and processes? I know that's been sort of a source of sort of constant review, but any view to any alterations in that over the next 12 to 18 months?

M
Marc Giroux
executive

Marl, it's Marc here. As you know, we've gone to market with a multi-service model, meaning that we leverage third party, we leverage click-and-collect and our own infrastructure, and we do our own delivery. And to your first question, the growth on our own delivery has been at the same level as third party. So consumers, there's a mix of need in the market.

Consumers are looking for quick delivery, but also planned delivery and click-and-collect. And all of these services have been growing at a steady rate. And as we look at the future of our platform, we will continue to go to market with multiple types of investment or platform through third-party marketplaces, click-and-collect and our own delivery.

And as you noticed in our comments, we just signed a new partnership with DoorDash, giving us a new channel to market through the DoorDash marketplace. So we're continuing in the same line as our strategy of the last few years.

M
Mark Petrie
analyst

Okay. And one last one. As you look within Q3 and then in Q4 to date, and you think about the buy Canadian trends, would you say that, that trend is stable, accelerating or decelerating?

M
Marc Giroux
executive

It's decelerating somewhat. Consumers are still buying more Canadians. So we're seeing more growth on Canadian product and non-Canadian product, but it has decelerated slightly.

Operator

[Operator Instructions]. And your next question will be from Vishal Shreedhar at National Bank.

A
Anshul Agarwala
analyst

This is Anshul in for Vishal Shreedhar. I wanted to follow up on your duplicate costs related to the new DCs. On the last conference call, was it fair to say that you lapsed the duplicate costs in Q2 and Q3 last year? And is it fair to expect SG&A leverage going forward, notwithstanding heightened third-party partnership fees?

N
Nicolas Amyot
executive

So I would say that -- so as you've mentioned, we lapsed duplicate costs in the third quarter this quarter, Q2 last year. Going forward, we would not have that lapse. So I think SG&A, we're always looking to create leverage and grew SG&A at a lower pace than revenue growth. So I think I would, yes, expect modest leverage in the coming quarters for SG&A.

Operator

And at this time, it appears we have no other questions registered. So I will turn the call back over to Sharon Kadoche.

S
Sharon Kadoche
executive

Thank you all for your interest in Metro, and please mark your calendars for our Q4 results on November 19. Thank you.

Operator

Thank you. Ladies and gentlemen, this does indeed conclude your conference call for today. Once again, thank you for attending. And at this time, we ask that you please disconnect your lines. Have a good day.

Earnings Call Recording
Other Earnings Calls